Blanc J J, Boschat J, Ollivier J P, Penther P
Arch Mal Coeur Vaiss. 1985 Jul;78(7):1097-102.
The effects of oral Sotalol were assessed by electrophysiological investigations in 6 patients with ventricular preexcitation (Wolff-Parkinson-White syndrome) and a short anterograde refractory period (less than or equal to 280 ms) of the accessory pathway. After 27 to 80 days (mean 41 +/- 19 days) of oral Sotalol (160 mg daily in 5 patients, 320 mg daily in 1 patient). The effective anterograde refractory period of the accessory pathway increased from 268 +/- 13 ms to 318 +/- 33 ms (less than 0.05); the shortest QR interval with appearances of preexcitation increased either during rapid atrial pacing (272 +/- 19 ms to 374 +/- 74 ms: p less than 0.05) or during induced atrial fibrillation (258 +/- 61 to 335 +/- 56 ms: p less than 0.01). The effective refractory period could only be measured in 4 cases during Sotalol therapy and increased by 10 ms, 130 ms and by at least 220 and 300 ms. During the repeat electrophysiological investigation the plasma concentrations of Sotalol ranged from 0.33 to 2.3 g/ml. These results show that oral Sotalol significantly increases the effective refractory periods of accessory pathways even when they are short under basal conditions. This product could therefore be effective in preventing the rapid ventricular response to atrial fibrillation in patients with the WPW syndrome and also in the prevention of reciprocating tachycardias.
通过电生理检查评估了口服索他洛尔对6例室性预激( Wolff - Parkinson - White综合征)且旁路前传不应期短(小于或等于280毫秒)患者的影响。在口服索他洛尔( 5例患者每日160毫克, 1例患者每日320毫克) 27至80天(平均41±19天)后。旁路的有效前传不应期从268±13毫秒增加到318±33毫秒( P<0.05) ;预激出现时最短的QR间期在快速心房起搏期间(从272±19毫秒增加到374±74毫秒: P<0.05)或诱发心房颤动期间(从258±61毫秒增加到335±56毫秒: P<0.01)均增加。在索他洛尔治疗期间仅在4例中测量了有效不应期,其分别增加了10毫秒、130毫秒以及至少220和300毫秒。在重复电生理检查期间,索他洛尔的血浆浓度范围为0.33至2.3微克/毫升。这些结果表明,即使在基础条件下旁路不应期短,口服索他洛尔也能显著增加旁路的有效不应期。因此,该产品可能对预防WPW综合征患者房颤时的快速心室反应以及预防折返性心动过速有效。